News for Genetic Signatures Limited (GSS.AX)

Published at

Feb 27, 2025 8:02 AM

by gurufocus.com

positive

positive

Genetic Signatures Ltd (ASX:GSS) (H1 2025) Earnings Call Highlights: Strong Sales Growth and Strategic US Expansion

Release Date: February 26, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Genetic Sign

GSS.AX

Read more →
Published at

Feb 27, 2025 6:06 AM

by gurufocus.com

positive

positive

Half Year 2025 Genetic Signatures Ltd Earnings Call Transcript

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NGSS.AX - Genetic Signatures LtdHalf Year 2025 Genetic Signatures Ltd Earnings CallFeb 26, 2025

GSS.AX

Read more →
Published at

Apr 22, 2024 4:02 AM

by themarketherald.com.au

positive

positive

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported a greenlight from the TGA.

GSS.AX

Read more →
Published at

Sep 4, 2023 2:00 AM

by themarketherald.com.au

mixed

mixed

ASX Today: Stocks to watch on Monday

Futures indicate the ASX200 will open slightly higher as a new trading week commences, driven by growing confidence that the US Federal Reserve will pause at its next rates meeting due to the increase in unemployment in the country.

IMU.AX GSS.AX DRE.AX IXR.AX SKC.AX

Read more →
Published at

Aug 25, 2023 1:58 AM

by themarketherald.com.au

mixed

mixed

ASX Today: Stocks to watch on Friday

Futures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum on Wall Street and leading the market to also close lower.

WES.AX BRN.AX BOT.AX ALK.AX GSS.AX

Read more →
Published at

Apr 30, 2023 7:20 PM

by stockhead.com.au

mixed

mixed

Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m+ quarterly sales

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

PSQ.AX PGC.AX OSX.AX OPT.AX OPT NOXOF NOX.AX IUGNF IMU.AX GSS.AX CYP.AX CKDXF BPH.AX ATX.AX 4DX.AX ZNO.AX SCU.AX RSH.AX PXSLY PXS.AX PAB.AX OCC.AX NC6.AX KZA.AX KMLXF IHL.AX IDT.AX FDMDF DVL.AX CMP.AX BITRF BIT.AX ARUXF AMT.AX ACR.AX 1AD.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX RNO.AX RHY.AX RHT.AX RGS.AX RAC.AX PYC.AX PNV.AX PCK.AX PBP.AX OVN.AX OSL.AX ONE.AX OIL.AX NYR.AX NXSCF NXS.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDR.AX MDC.AX MDBIF LBT.AX IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX ICR.AX HCT.AX GTG.AX GLH.AX EYE.AX DXB.AX CSL.AX CPH.AX CGS.AX CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX AT1.AX ARX.AX AMDHF ALC.AX ADR.AX ADO.AX 1ST.AX

Read more →
Published at

Mar 15, 2023 9:00 PM

by stockhead.com.au

mixed

mixed

Rise and Shine: Everything you need to know before the ASX opens

On Stockhead today, Taylor Collison is backing Genetic Signatures (ASX:GSS) to Outperform saying the medtech's PT could triple.

VTG.AX VRC.AX SIX.AX RLG.AX RKN.AX PYR.AX PRS.AX NTI.AX NCZ.AX MNS.AX MMI.AX MCT.AX GSS.AX ENX.AX EGY.AX CR9.AX CLE.AX APC.AX WRM.AX VAL.AX TD1.AX SRJ.AX PVS.AX POL.AX OPL.AX MCM.AX LCY.AX ICR.AX GWR.AX CPT.AX AKN.AX TKL.AX OLI.AX MXO.AX MTH.AX KEY.AX GTG.AX

Read more →
Published at

Mar 15, 2023 5:50 PM

by stockhead.com.au

positive

positive

MoneyTalks: Zip share price could quadruple while Genetic Signatures to triple, say these brokers

Three ASX stocks, Good Drinks (GDA), Genetic Signatures (GSS) and Zip (ZIP) have received recommendations with strong price targets.

GSS.AX GDA.AX

Read more →
Published at

Mar 5, 2023 7:20 PM

by stockhead.com.au

mixed

mixed

Check Up: Almost half a billion US dollars raised to bring back mammoth, dodo, and Tassie tiger

Colossal Biosciences’ plans to bring the Tasmanian tiger and woolly mammoth back to life, but now it’s also betting on the iconic dodo.

TD1.AX RGS.AX RAC.AX FFC.AX EZL.AX PYC.AX PAB.AX OPT.AX OPT MX1.AX CMP.AX CKDXF AMT.AX VTG.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX PXSLY PXS.AX PSQ.AX PNV.AX PGC.AX PBP.AX ONE.AX OCC.AX NYR.AX NC6.AX MVF.AX MEM.AX MEB.AX MDBIF LBT.AX IVX.AX IPDQF IPD.AX IMM.AX HCT.AX GTG.AX GSS.AX EYE.AX CGS.AX CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX ATX.AX ARUXF AMDHF ADR.AX ACR.AX

Read more →
Published at

Feb 3, 2023 7:03 AM

by stockhead.com.au

mixed

mixed

Weekly Small Cap and IPO Wrap: Local market performs precisely as well as Adani most certainly didn’t

The ASX has performed well this week, Lode Resources aced the Small Caps win and Big Gun Adani is tanking – hard – and it just keeps getting worse.

YPB.AX VIP.AX SMX.AX SKN.AX RGS.AX RCW.AX OAU.AX OAR.AX NWC.AX MOB.AX MMM.AX MME.AX MDC.AX M8S.AX GLV.AX GBE.AX FIJ.AX BKY.AX AUK.AX AMD.AX AHQDB.AX AHQ.AX 3DA.AX WML.AX WFL.AX WBE.AX TZLTF TZL.AX PKO.AX OPL.AX LDR.AX KSN.AX GSS.AX GLL.AX FRM.AX ENX.AX ENV.AX BYOGF BUGLF BLG.AX VKA.AX TFL.AX STM.AX SCT.AX MCM.AX IHR.AX GTG.AX CAI.AX BAS.AX

Read more →
Published at

Feb 1, 2023 5:46 PM

by stockhead.com.au

mixed

mixed

Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food citing safety reasons, but the CBD index keeps going up.

PYC.AX PSQ.AX PGC.AX MSB.AX KZA.AX EYE.AX DVL.AX CAN.AX BXN.AX BNOEF BNO.AX ADO.AX SOMNF SOM.AX RSH.AX RHT.AX RGS.AX OSX.AX OSL.AX ONE.AX OIL.AX NXSCF NXS.AX MEB.AX MDC.AX MDBIF KMLXF IVX.AX IUGNF IMU.AX IDT.AX GLH.AX CYP.AX CMP.AX CAJ.AX AT1.AX ADR.AX 1ST.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SCU.AX RNO.AX RHY.AX RAC.AX PXSLY PXS.AX PNV.AX PCK.AX PBP.AX PAB.AX OVN.AX OPT.AX OPT OCC.AX NYR.AX NOXOF NOX.AX NC6.AX MXC.AX MX1.AX MVF.AX MEM.AX MDR.AX LBT.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX ICR.AX HCT.AX GTG.AX GSS.AX FDMDF DXB.AX CPH.AX CKDXF CGS.AX CALZF BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX ARX.AX ARUXF AMT.AX AMDHF ALC.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Jan 19, 2023 5:50 PM

by stockhead.com.au

mixed

mixed

Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI Inc says it is on a mission to halve the world's blindness with its smartphone-based device.

ZNO.AX ZLD.AX RAP.AX PSQ.AX PIQ.AX PBP.AX PAA.AX MXC.AX IPDQF IPD.AX IDT.AX GLH.AX CGS.AX BXN.AX 1AD.AX SOMNF SOM.AX SHL.AX RSH.AX RGS.AX PGC.AX PCK.AX OVN.AX OSX.AX OSL.AX OIL.AX NYR.AX NXSCF NXS.AX MX1.AX MDC.AX LBT.AX KZIA KZA.AX KMLXF IVX.AX IMMP IMM.AX IHL.AX GSS.AX FDMDF DVL.AX CYP.AX CPH.AX CAN.AX BWXXF BWX.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX AT1.AX ARX.AX AKU.TO AKU ADR.AX 4DX.AX 1ST.AX VTG.AX VLS.AX UBI.AX SCU.AX RNO.AX RHY.AX RHT.AX RAC.AX PYC.AX PXSLY PXS.AX PNV.AX PAB.AX OPT.AX OPT ONE.AX OCC.AX NOXOF NOX.AX NC6.AX MVF.AX MEM.AX MEB.AX MDR.AX MDBIF IUGNF IMU.AX IMRNW IMRN IMC.AX ICR.AX HCT.AX EYE.AX DXB.AX CMP.AX CKDXF CALZF CAJ.AX ATX.AX ARUXF AMT.AX AMDHF ALC.AX ADO.AX ACR.AX

Read more →
Published at

Jan 4, 2023 6:02 PM

by stockhead.com.au

mixed

mixed

Check Up: Moderna posts crazy cancer vaccine results, says melanoma recurrence down by almost half

Moderna’s stock price rose in late December after the company revealed that a vaccine for melanoma showed encouraging results.

TD1.AX RSH.AX PCK.AX MX1.AX KMLXF DVL.AX CAJ.AX BNOEF BNO.AX ARX.AX ADR.AX 1ST.AX ZNO.AX RHY.AX RAC.AX PYC.AX PSQ.AX PGC.AX OVN.AX OSX.AX ONE.AX OCC.AX NOXOF NOX.AX NC6.AX MDC.AX KZA.AX IPDQF IPD.AX IDT.AX GTG.AX CYP.AX CPH.AX CAN.AX BXN.AX BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX ZLD.AX VTG.AX VLS.AX UBI.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX RGS.AX PXSLY PXS.AX PNV.AX PBP.AX PAB.AX OSL.AX OPT.AX OPT OIL.AX NYR.AX NXSCF NXS.AX MXC.AX MVF.AX MEM.AX MDR.AX LBT.AX IVX.AX IUGNF IMU.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX ICR.AX HCT.AX GSS.AX GLH.AX FDMDF EYE.AX DXB.AX CMP.AX CKDXF CGS.AX CALZF AT1.AX ARUXF AMT.AX AMDHF ALC.AX ADO.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Nov 30, 2022 8:10 PM

by stockhead.com.au

mixed

mixed

Check Up: The world's most expensive drug costs $3.5 MILLION a shot

The US FDA has just approved the world’s most expensive drug. CSL Behring’s hemophilia B gene therapy costs US$3.5m a dose.

PAB.AX OCC.AX NC6.AX MDR.AX IMM.AX GTG.AX GSS.AX EYE.AX CSLN.MX CSLLY CSL.AX CMXHF BPH.AX SHL.AX RAC.AX PSQ.AX ONE.AX NYR.AX NXSCF NXS.AX MXC.AX KZA.AX FDMDF DXB.AX DVL.AX CYP.AX CPH.AX CGS.AX AT1.AX ARX.AX ARUXF AMDHF ALC.AX ACR.AX 4DX.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX SCU.AX RSH.AX RNO.AX RHY.AX RHT.AX RGS.AX PYC.AX PXSLY PXS.AX PNV.AX PGC.AX PCK.AX PBP.AX OVN.AX OSX.AX OSL.AX OPT.AX OPT OIL.AX NOXOF NOX.AX MX1.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KMLXF IVX.AX IUGNF IPDQF IPD.AX IMU.AX IMRNW IMRN IMC.AX IHL.AX IDT.AX ICR.AX HCT.AX GLH.AX CMP.AX CKDXF CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX AMT.AX ADR.AX ADO.AX 1ST.AX 1AD.AX

Read more →
Published at

Nov 23, 2022 7:50 PM

by stockhead.com.au

mixed

mixed

How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have fallen out of favour in 2022 with a a rotation out of growth into value sectors but could it also do with better PR?

VTG.AX NEU.AX MXC.AX KZA.AX CSL.AX COH.AX BWXXF BWX.AX AT1.AX ADR.AX ADO.AX ZNO.AX ZLD.AX UBI.AX TD1.AX SHL.AX RSH.AX RHT.AX RAC.AX PNV.AX PBP.AX OVN.AX OSX.AX OSL.AX OCC.AX NOXOF NOX.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KMLXF IUGNF IMU.AX ICS.AX ICR.AX EYE.AX CPH.AX CMP.AX CALZF BXN.AX AMDHF 1ST.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHY.AX RGS.AX PYC.AX PXSLY PXS.AX PSQ.AX PGC.AX PCK.AX PAB.AX OPT.AX OPT ONE.AX OIL.AX NYR.AX NXSCF NXS.AX MX1.AX MDR.AX IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX IDT.AX HCT.AX GTG.AX GSS.AX GLH.AX FDMDF DXB.AX DVL.AX CYP.AX CKDXF CGS.AX CAN.AX CAJ.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX ARX.AX ARUXF AMT.AX ALC.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Nov 3, 2022 8:30 PM

by stockhead.com.au

mixed

mixed

Rise and Shine: Everything you need to know before the ASX opens

Rise and Shine: Everything you need to know before the ASX opens

SIH.AX NZS.AX M8S.AX HIQ.AX EMT.AX ADR.AX TSC.AX SUH.AX SRI.AX NOV.AX NC6.AX IVZ.AX ICG.AX COB.AX CGF.AX ATU.AX ANL.AX ADV.AX PXXXF OAU.AX OAR.AX NUHRF NUH.AX MCT.AX KTG.AX GSS.AX AQX.AX AQD.AX A1M.AX

Read more →
Published at

Nov 3, 2022 6:57 AM

by stockhead.com.au

mixed

mixed

Closing Bell: Local market on its knees after Fed’s big night of being tight; Norfolk Minerals up 137%

ASX 200 closes with -1.8% loss. Small cap index down 1% but up way more than 100% Norfolk Minerals - the real NFL.

SIH.AX MOZ.AX M8S.AX HIQ.AX EMT.AX CCG.AX ADR.AX A1M.AX TSLA TSC.AX SRI.AX OAR.AX NC6.AX IVZ.AX ICG.AX BVS.AX ATU.AX ANL.AX ADV.AX SUH.AX PXXXF OAU.AX NUHRF NUH.AX NOV.AX MCT.AX KTG.AX GSS.AX COB.AX AQX.AX AQD.AX

Read more →
Published at

Nov 2, 2022 8:30 PM

by stockhead.com.au

mixed

mixed

Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations

Four ASX healthcare stocks have been rated as a ‘Strong Buy' by Morningstar’s consensus of brokers, making them hot tips.

ZNO.AX RHT.AX LBT.AX KZA.AX IUGNF IMU.AX ICR.AX EPN.AX ARX.AX ARUXF AMT.AX ALC.AX ACR.AX 1ST.AX ZLD.AX RAC.AX PNV.AX PBP.AX ONE.AX OIL.AX NXSCF NXS.AX MDR.AX IPDQF IPD.AX IMRNW IMRN IMC.AX GTG.AX GSS.AX GLH.AX FDMDF EYE.AX CYP.AX CALZF BNOEF BNO.AX 4DX.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX SCU.AX RSH.AX RNO.AX RHY.AX RGS.AX PYC.AX PXSLY PXS.AX PSQ.AX PGC.AX PCK.AX PAB.AX OVN.AX OSX.AX OSL.AX OPT.AX OPT OCC.AX NYR.AX NOXOF NOX.AX NC6.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF KMLXF IVX.AX IMM.AX IHL.AX IDT.AX HCT.AX DXB.AX DVL.AX CPH.AX CMP.AX CKDXF CGS.AX CAN.AX CAJ.AX BXN.AX BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX AT1.AX AMDHF ADR.AX ADO.AX 1AD.AX

Read more →
Published at

Oct 20, 2022 9:00 PM

by stockhead.com.au

mixed

mixed

Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?

There were 191 ASX IPOs in calendar year 2021, and 15 of them were biotech stocks.But in 2022 there were only 3 biotech listings.

PXSLY PXS.AX PAB.AX OSL.AX MEM.AX ILA.AX GLH.AX CAJ.AX BPH.AX AMDHF AGN.AX ZLD.AX UBI.AX TD1.AX SCU.AX RSH.AX RNO.AX RHY.AX RGS.AX PYC.AX PGC.AX PBP.AX OSX.AX OPT.AX OPT OIL.AX OCC.AX NXSCF NXS.AX NOXOF NOX.AX NC6.AX MXC.AX MEB.AX MDR.AX MDC.AX MDBIF KMLXF IPDQF IPD.AX IMRNW IMRN IMC.AX IHL.AX HXL.AX GTG.AX EYE.AX DVL.AX CPH.AX CKDXF BWXXF BWX.AX BITRF BIT.AX AT1.AX ARUXF ACR.AX 1ST.AX ZNO.AX VTG.AX VLS.AX SOMNF SOM.AX RHT.AX RAC.AX PSQ.AX PNV.AX PCK.AX OVN.AX ONE.AX NYR.AX MX1.AX MVF.AX LBT.AX KZA.AX IVX.AX IUGNF IMU.AX IMM.AX IDT.AX ICR.AX HCT.AX GSS.AX FDMDF DXB.AX CYP.AX CMP.AX CGS.AX CAN.AX CALZF BXN.AX BNOEF BNO.AX ATX.AX ARX.AX AMT.AX ALC.AX ADR.AX ADO.AX ACW.AX 4DX.AX 1AD.AX

Read more →
Published at

Oct 5, 2022 9:30 PM

by stockhead.com.au

mixed

mixed

Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice

Blood clot was top of biotech news this week after researchers revealed new discovery that could prevent it without risk of bleeding.

NOXOF NOX.AX JNJ EX1.AX DJNJ3.BA DJNJ2.BA CGS.AX RCEL PYC.AX PBP.AX OPT.AX OPT OCC.AX NC6.AX MDC.AX KZIA KZA.AX IVX.AX IDT.AX GSS.AX EOFBF EOF.AX DVL.AX CYC.AX CSLN.MX CSLLY CSL.AX CMXHF CKDXF CAN.AX BPH.AX AVH.AX ARX.AX ARUXF AFP.AX ACR.AX 1AD.AX ZLD.AX WFL.AX VTG.AX VLS.AX SPL.AX SCU.AX RNO.AX RGS.AX RAC.AX QURE PXSLY PXS.AX PAB.AX OSL.AX NYR.AX NXSCF NXS.AX MYX.AX MXC.AX MSB.AX MESO MEOBF MEM.AX LGP.AX IUGNF IMU.AX IMRNW IMRN IMMP IMM.AX IMC.AX IHL.AX GTG.AX GENE DXB.AX CYP.AX CPH.AX CGB.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX ADO.AX

Read more →